New Feature: See Wall Street analyst ratings directly on Finviz charts for deeper context into price action.

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Latest News

Feb-20	Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down IMCR Zacks
Feb-20	Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term EXEL Zacks
Feb-19	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 KNSA GlobeNewswire
Feb-19	BHC Stock Down on Q4 Earnings Miss, Salix Drives Revenue Growth ALKS Zacks
Feb-19	Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know KNSA Zacks
Feb-19	Shopify, eBay upgraded: Wall Street's top analyst calls KNSA The Fly
Feb-19	ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up ALKS Zacks
Feb-18	FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma ALKS Zacks
Feb-18	Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark ALKS Zacks
Feb-18	Expand Energy Q4 Earnings Call Highlights EXEL MarketBeat
Feb-18	EU Approves Novo Nordisk's Higher-Dose Wegovy for Obesity Patients ALKS Zacks
Feb-18	Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year? ALKS Zacks
Feb-18	Cytokinetics Wins EU Approval for Cardiovascular Drug Myqorzo ALKS Zacks
Feb-18	Immunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 IMCR GlobeNewswire
Feb-17	Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? ALKS Zacks

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.